There are known outcome disparities between Black and White patients with pancreatic neuroendocrine tumors (pNETs). Multiple retrospective series have found that Black patients have more advanced ...

Pancreatic ductal adenocarcinoma (PDAC) remains a treatment-refractory disease and existing molecular subtypes do not inform clinical decisions. Previously-identified bulk transcriptomic subtypes of ...